The Activation of Escherichia coli Aspartate Transcarbamylase by ATP

International audienc

Société d'histoire du Droit et des Institutions des Pays Flamands, Picards et Wallons Journées Internationales de Namur (20-23 mai 1982)

Ankum Hans, Platelle Henri, Cauchies Jean-Marie, Stas Françoise, Roelofsen C.-G., Moorman van Kappen O., Hansotte Georges, Demars-Sion Véronique, D'Arras d'Haudrecy L., Dupont-Bouchat S. Société d'histoire du Droit et des Institutions des Pays Flamands, Picards et Wallons Journées Internationales de Namur (20-23 mai 1982). In: Revue du Nord, tome 65, n°256, Janvier-mars 1983. Archéologie. pp. 221-231

Société d'histoire du Droit et des Institutions des Pays Flamands, Picards et Wallons Journées Internationales de Namur (20-23 mai 1982)

Ankum Hans, Platelle Henri, Cauchies Jean-Marie, Stas Françoise, Roelofsen C.-G., Moorman van Kappen O., Hansotte Georges, Demars-Sion Véronique, D'Arras d'Haudrecy L., Dupont-Bouchat S. Société d'histoire du Droit et des Institutions des Pays Flamands, Picards et Wallons Journées Internationales de Namur (20-23 mai 1982). In: Revue du Nord, tome 65, n°256, Janvier-mars 1983. Archéologie. pp. 221-231

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

The purpose of this phase 1/2 study was to evaluate toxicity, tumor evolution and immunologic response following administration of a fixed dose of a recombinant MAGE-3 protein by subcutaneous and intradermal routes in the absence of immunologic adjuvant. Thirty-two patients with detectable metastatic melanoma expressing gene MAGE-3 were included and 30 received at least one injection with a fixed dose of a ProtD-MAGE-3 fusion protein. The immunization schedule included 6 intradermal and subcutaneous injections at 3-week intervals. Afterward, patients without major tumor progression who required other treatments received additional vaccinations at increasing time intervals. The vaccine was generally well tolerated. Among the 26 patients who received at least 4 vaccinations, we observed 1 partial response and 4 mixed responses. For these 5 responding patients, time to progression varied from 3.5 to 51+ months. An anti-MAGE-3 CD4 T-lymphocyte response was detected in 1 out of the 5 responding patients. The majority of patients had no anti-MAGE-3 antibody response. The clinical and immunologic responses generated by the vaccine are rather limited. Nevertheless, given the potential antitumor efficacy and the very mild toxicity of vaccinations, further studies combining MAGE proteins and/or peptides with potent immunologic adjuvants are warranted, not only in metastatic melanoma, but also in the adjuvant setting. (c) 2005 Wiley-Liss, Inc